A fund dedicated to the digital transformation of healthcare, Kurma Diagnostics II has a size of 83 million euros after a first closing in 2021 to invest in diagnostics digital and diagnostic solutions

An investment fund dedicated to new therapeutic solutions for diseases with high medical need.

Kurma Biofund III aims to invest in projects and companies in the Life Sciences sector in Europe, marginally in the United States, meeting an important medical need, by creating one third of the companies in which it invests.

Paris Saclay Seed Fund is an acceleration fund financing the projects of companies resulting from the technologies developed within the University of Paris Saclay and its members.

The fund is co-managed by Partech (digital) and Kurma Partners (health). 15 million euros are dedicated to health.

Kurma Diagnostics, with a size of approximately €35 million, invests in companies or projects in the field of diagnostics disruptive solutions and generate commercial revenues within 3 to 5 years.

An investment fund dedicated to new therapeutic solutions and in particular to rare diseases.

Kurma Biofund II aims to invest in projects and companies in the Life Sciences sector in Europe, responding to an important medical need, with a focus on Rare Diseases.

An investment fund dedicated to life sciences.

Kurma Biofund I was launched in November 2009 at 51 million € and was invested in a portfolio of 11 companies in the Life Sciences sector.

Within this portfolio, five companies were created by the fund in partnership with partner research institutes